AbbVie’s Rinvoq racked up another approval late Wednesday afternoon.
The drug is now OK’d in adults with moderately to severely active ulcerative colitis who have had an inadequate response or intolerance to one or more TNF blockers, AbbVie said in a press release. It’s the first approval for the drug in gastroenterology, the company added, with data stemming from three Phase III studies.
“There remains an unmet need for patients with moderately to severely active UC, who suffer from debilitating symptoms that are often unpredictable and burdensome,” said Thomas Hudson, AbbVie CSO. “With the approval of Rinvoq as a new treatment option, AbbVie continues our leadership in advancing research that can help impact the lives of people living with ulcerative colitis.”